|
Jul 31
|
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jul 29
|
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a favorite amongst institutional investors who own 54%
|
|
May 20
|
Xeris Announces Details for Analyst & Investor Day
|
|
Apr 17
|
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
|
|
Mar 28
|
Xeris Announces Changes to Its Board of Directors
|
|
Mar 27
|
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?
|
|
Mar 17
|
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
|